Monkeypox

This Phase 3 study is testing the MVA-BN mpox vaccine in 344 infants and children aged 4 to 24 months in the Democratic Republic of the Congo, a region heavily affected by mpox. Researchers are comparing a standard dose to a half-dose to see if the lower dose is still effective a…

This study tests whether the MVA-BN mpox vaccine (Jynneos) works as well when made in quail cells instead of chicken cells. About 970 healthy adults aged 18 to 49 will receive two doses four weeks apart. Researchers will compare immune responses and side effects between the two v…

This Phase 3 trial is testing the safety and immune response of the MVA-BN mpox vaccine in 359 pregnant and postpartum women in the Democratic Republic of the Congo. Some women receive the vaccine during pregnancy, others right after giving birth, and a small group gets it as an …

This study tests the MVA-BN vaccine in 460 children aged 2 to 12 years, comparing their immune response and safety to adults. All participants receive two doses four weeks apart. The goal is to see if the vaccine can prevent smallpox, mpox, and related orthopoxvirus infections in…

This study tests whether the antiviral drug tecovirimat can help people with monkeypox heal faster. About 480 adults and teens (14+) with active lesions will receive either tecovirimat or a placebo, alongside standard care. The main goal is to see how quickly skin and mouth sores…

This Canadian study tests whether the antiviral drug tecovirimat (TPOXX) helps non-hospitalized adults with monkeypox recover faster. About 120 participants will receive either the drug or a placebo. The main goal is to see how quickly skin lesions heal and whether running such a…

This trial tests whether giving the smallpox vaccine to people who have been exposed to mpox can prevent them from getting sick or reduce the severity of the disease. It involves about 3,000 household members of people with confirmed mpox, who receive either the vaccine or a cont…

This study is testing whether the MVA-BN mpox vaccine is safe and triggers a strong immune response in 600 adults living with HIV in Kinshasa, DRC. Participants receive two vaccine doses 28 days apart and are grouped by their CD4 count. The goal is to see if the vaccine works wel…

This Phase 3 trial in Colombia tests the LC16m8 vaccine, originally developed for smallpox, to see if it can prevent mpox in people at high risk, such as men who have sex with men and those with HIV. About 8,686 participants will be randomly assigned to get the vaccine right away…

This study looks at how well the mpox vaccine works and how safe it is in people with HIV compared to those without HIV. About 174 adults who either recently got the mpox vaccine or had a recent mpox infection will take part. The goal is to fill important knowledge gaps and help …

This study tests a new AI-powered toolkit designed to help public health officials at local CDC offices respond more quickly to emerging infectious diseases such as COVID-19, mpox, influenza, and dengue. The toolkit combines data analysis, risk assessment, decision support, and e…

This study follows 300 adults in the Democratic Republic of the Congo who received either the MVA-BN or LC16m8 mpox vaccine as part of a national campaign. Researchers collect blood samples at several time points to measure how well the vaccines trigger and maintain antibodies ag…